The Suppression Effects of Thalidomide on Human Lung Fibroblasts: Cell Proliferation, Vascular Endothelial Growth Factor Release, and Collagen Production

Overview

Journal Lung

Specialty Pulmonary Medicine

Date 2013 Jun 1

PMID 23722461

Citations 6

Authors

Ching-Min Tseng

Yi-Han Hsiao

Vincent Yi-Fong Su

Kang-Cheng Su

Yu-Chung Wu

Kuo-Ting Chang

Diahn-Warng Perng

Affiliations

Soon will be listed here.

Abstract

Background: Expression of transforming growth factor (TGF)-β1 and increases in angiogenesis and deposition of extracellular matrix are the key features of tracheal granulation formation. The aim of this study was to investigate the potential role of thalidomide in preventing granulation tissue formation from the aspect of cellular effects in vitro, including fibroblast proliferation, vascular endothelial growth factor (VEGF) release, and collagen production.

Methods: Human lung fibroblasts were obtained from bronchus and cultured. The effects of thalidomide on cell proliferation, migration, TGF-β1-induced VEGF, and signal pathway were investigated.

Results: Thalidomide (20 μM) not only inhibited cell proliferation after 24 h [fold increase of cell number, 0.85 ± 0.09 vs. 1.47 ± 0.14 (treatment vs. control group); P < 0.01] and 48 h of incubation (0.85 ± 0.10 vs. 1.97 ± 0.12; P < 0.001), it also inhibited cell migration and slowed wound closure at 24 h (P < 0.001). Thalidomide significantly attenuated TGF-β1-induced VEGF expression at both the mRNA and protein levels. Incubation of thalidomide with cells stimulated with TGF-β1 significantly inhibited their production of collagen. Thalidomide inhibited Smad3, STAT3, and subsequent p44/42 kinase phosphorylation.

Conclusion: Thalidomide may inhibit human fibroblast proliferation and it is worthy of further in vivo investigation.

Citing Articles

Advances in studies on tracheal stent design addressing the related complications.

Chen S, Du T, Zhang H, Zhang Y, Qiao A Mater Today Bio. 2024; 29:101263.

PMID: 39399242 PMC: 11467681. DOI: 10.1016/j.mtbio.2024.101263.

Targeting the microenvironment in the treatment of arteriovenous malformations.

Seebauer C, Wiens B, Hintschich C, Platz Batista da Silva N, Evert K, Haubner F Angiogenesis. 2023; 27(1):91-103.

PMID: 37733132 PMC: 10881762. DOI: 10.1007/s10456-023-09896-3.

Modulation of COX-2 and NADPH oxidase-4 by alpha-lipoic acid ameliorates busulfan-induced pulmonary injury in rats.

Elhadidy M, Elmasry A, Elsayed H, El-Nablaway M, Hamed S, Elalfy M Heliyon. 2021; 7(10):e08171.

PMID: 34746462 PMC: 8551514. DOI: 10.1016/j.heliyon.2021.e08171.

Systemic Immunomodulatory Effects of Combinatorial Treatment of Thalidomide and Dexamethasone on T Cells and Other Immune Cells.

Kim E, Kim J, Choi H, Lee H, Lee J, Kim M Yonsei Med J. 2021; 62(2):137-148.

PMID: 33527793 PMC: 7859687. DOI: 10.3349/ymj.2021.62.2.137.

Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets.

Kim E, Lee J, Kim J, Song S, Joo D, Huh K Immunology. 2017; 152(4):628-637.

PMID: 28758197 PMC: 5680070. DOI: 10.1111/imm.12804.

References

Karagiannidis C, Velehorschi V, Obertrifter B, Macha H, Linder A, Freitag L . High-level expression of matrix-associated transforming growth factor-beta1 in benign airway stenosis. Chest. 2006; 129(5):1298-304. DOI: 10.1378/chest.129.5.1298. View

Komorowski J, Jerczynska H, Siejka A, Baranska P, Lawnicka H, Pawlowska Z . Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci. 2005; 78(22):2558-63. DOI: 10.1016/j.lfs.2005.10.016. View

Verrecchia F, Chu M, Mauviel A . Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem. 2001; 276(20):17058-62. DOI: 10.1074/jbc.M100754200. View

Bartoli M, Platt D, Lemtalsi T, Gu X, Brooks S, Marrero M . VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003; 17(11):1562-4. DOI: 10.1096/fj.02-1084fje. View

Moreira A, Friedlander D, Shif B, Kaplan G, Zagzag D . Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol. 1999; 43(2):109-14. DOI: 10.1023/a:1006202700039. View

Or R, Feferman R, Shoshan S . Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol. 1998; 26(3):217-21. View

Bartlett J, Dredge K, Dalgleish A . The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004; 4(4):314-22. DOI: 10.1038/nrc1323. View

Grillo H, Donahue D, Mathisen D, Wain J, Wright C . Postintubation tracheal stenosis. Treatment and results. J Thorac Cardiovasc Surg. 1995; 109(3):486-92; discussion 492-3. DOI: 10.1016/S0022-5223(95)70279-2. View

Bartoli M, Gu X, Tsai N, Venema R, Brooks S, Marrero M . Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem. 2000; 275(43):33189-92. DOI: 10.1074/jbc.C000318200. View

10.

Corral L, Haslett P, Muller G, Chen R, Wong L, Ocampo C . Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999; 163(1):380-6. View

11.

Pokharel R, Maeda K, Yamamoto T, Noguchi K, Iwai Y, Nakamura H . Expression of vascular endothelial growth factor in exuberant tracheal granulation tissue in children. J Pathol. 1999; 188(1):82-6. DOI: 10.1002/(SICI)1096-9896(199905)188:1<82::AID-PATH324>3.0.CO;2-4. View

12.

Blobe G, Schiemann W, Lodish H . Role of transforming growth factor beta in human disease. N Engl J Med. 2000; 342(18):1350-8. DOI: 10.1056/NEJM200005043421807. View

13.

Lee Y, Hung M, Liu L, Chang K, Chou T, Wang Y . The roles of transforming growth factor-β₁ and vascular endothelial growth factor in the tracheal granulation formation. Pulm Pharmacol Ther. 2010; 24(1):23-31. DOI: 10.1016/j.pupt.2010.10.016. View

14.

Ashcroft G, Yang X, Glick A, Weinstein M, Letterio J, Mizel D . Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol. 1999; 1(5):260-6. DOI: 10.1038/12971. View

15.

Ward R, April M . Mitomycin-C in the treatment of tracheal cicatrix after tracheal reconstruction. Int J Pediatr Otorhinolaryngol. 1998; 44(3):221-6. DOI: 10.1016/s0165-5876(98)00061-5. View

16.

Liu H, Chen J, Holinger L, GONZALEZ-CRUSSI F . Histopathologic fundamentals of acquired laryngeal stenosis. Pediatr Pathol Lab Med. 1995; 15(5):655-77. DOI: 10.3109/15513819509027004. View

17.

Rea F, Callegaro D, Loy M, Zuin A, Narne S, Gobbi T . Benign tracheal and laryngotracheal stenosis: surgical treatment and results. Eur J Cardiothorac Surg. 2002; 22(3):352-6. DOI: 10.1016/s1010-7940(02)00342-1. View

18.

Niu G, Wright K, Huang M, Song L, Haura E, Turkson J . Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21(13):2000-8. DOI: 10.1038/sj.onc.1205260. View

19.

Keifer J, Guttridge D, Ashburner B, Baldwin Jr A . Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001; 276(25):22382-7. DOI: 10.1074/jbc.M100938200. View

20.

Strauss R, Bate J, Nischal K, Clayton T, Gooi J, Darling J . A child with laryngo-onychocutaneous syndrome partially responsive to treatment with thalidomide. Br J Dermatol. 2006; 155(6):1283-6. DOI: 10.1111/j.1365-2133.2006.07464.x. View